Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

被引：63

作者：

Costa, Luciano J. ^{[1
]}

Maddocks, Kami ^{[2
]}

Epperla, Narendranath ^{[3
]}

Reddy, Nishitha M. ^{[4
]}

Karmali, Reem ^{[5
]}

Umyarova, Elvira ^{[6
]}

Bachanova, Veronika ^{[7
]}

Costa, Cristiana ^{[8
]}

Glenn, Martha J. ^{[9
]}

Chavez, Julio C. ^{[10
]}

Calzada, Oscar ^{[11
]}

Lansigan, Frederick ^{[8
]}

Nasheed, Hossain ^{[12
]}

Barta, Stefan K. ^{[12
]}

Zhou, Zheng ^{[13
]}

Jaglal, Michael ^{[10
]}

Chhabra, Saurabh ^{[6
]}

Hernandez-Ilizaliturri, Francisco ^{[14
]}

Xavier, Ana C. ^{[15
]}

Mehta, Amitkumar ^{[1
]}

Peker, Deniz ^{[16
]}

Forero-Torres, Andreas ^{[1
]}

Al-Mansour, Zeina ^{[17
]}

Evens, Andrew M. ^{[17
]}

Cohen, Jonathon B. ^{[11
]}

Flowers, Christopher R. ^{[11
]}

Fenske, Timothy S. ^{[3
]}

Hamadani, Mehdi ^{[3
]}

机构：

[1] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

[2] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

[3] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA

[4] Vanderbilt Univ, Div Hematol & Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA

[5] Rush Univ, Div Hematol Oncol & Cell Therapy, Chicago, IL 60612 USA

[6] Med Univ South Carolina, Div Hematol & Oncol, Charleston, SC 29425 USA

[7] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[8] Dartmouth Hitchcock Med Ctr, Dept Hematol & Oncol, Lebanon, NH 03766 USA

[9] Univ Utah, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[10] H Lee Moffitt Canc Ctr & Res, Dept Malignant Hematol, Tampa, FL USA

[11] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[13] Univ Massachusetts, Div Hematol Oncol, Worcester, MA 01605 USA

[14] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA

[15] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA

[16] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA

[17] Tufts Univ, Div Hematol Oncol, Boston, MA 02111 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2017年 / 92卷 / 02期

关键词：

NON-HODGKINS-LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; CHIMERIC ANTIGEN RECEPTOR; AUTOLOGOUS TRANSPLANTATION; T-CELLS; COMPLETE RESPONSE; R-CHOP; DLBCL; ERA; IPI;

D O I：

10.1002/ajh.24615

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2-3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.

引用

页码：161 / 170

页数：10

共 31 条

[1] Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy [J].

Alici, Suleyman ;

Bavbek, Sevil ;

Basaran, Mert ;

Onat, Haluk .

ADVANCES IN THERAPY, 2006, 23 (04) :534-542

[2]

[Anonymous], BLOOD

[3] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[4] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [J].

Brudno, Jennifer N. ;

Somerville, Robert P. T. ;

Shi, Victoria ;

Rose, Jeremy J. ;

Halverson, David C. ;

Fowler, Daniel H. ;

Gea-Banacloche, Juan C. ;

Pavletic, Steven Z. ;

Hickstein, Dennis D. ;

Lu, Tangying L. ;

Feldman, Steven A. ;

Iwamoto, Alexander T. ;

Kurlander, Roger ;

Maric, Irina ;

Goy, Andre ;

Hansen, Brenna G. ;

Wilder, Jennifer S. ;

Blacklock-Schuver, Bazetta ;

Hakim, Frances T. ;

Rosenberg, Steven A. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1112-+

[5] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[6] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[7] MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study [J].

Copie-Bergman, Christiane ;

Cuilliere-Dartigues, Peggy ;

Baia, Maryse ;

Briere, Josette ;

Delarue, Richard ;

Canioni, Danielle ;

Salles, Gilles ;

Parrens, Marie ;

Belhadj, Karim ;

Fabiani, Bettina ;

Recher, Christian ;

Petrella, Tony ;

Ketterer, Nicolas ;

Peyrade, Frederic ;

Haioun, Corinne ;

Nagel, Inge ;

Siebert, Reiner ;

Jardin, Fabrice ;

Leroy, Karen ;

Jais, Jean-Philippe ;

Tilly, Helve ;

Molina, Thierry Jo ;

Gaulard, Philippe .

BLOOD, 2015, 126 (22) :2466-2474

[8] Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation [J].

Costa, L. J. ;

Micallef, I. N. ;

Inwards, D. J. ;

Johnston, P. B. ;

Ansell, S. M. .

BONE MARROW TRANSPLANTATION, 2008, 41 (08) :715-720

[9]

Costa LJ, 2016, AM J HEMATOL, V00, DOI [10.1002/ajh.24615, DOI 10.1002/AJH.24615]

[10] MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation [J].

Cuccuini, Wendy ;

Briere, Josette ;

Mounier, Nicolas ;

Voelker, Hans-Ullrich ;

Rosenwald, Andreas ;

Sundstrom, Christer ;

Cogliatti, Sergio ;

Hirchaud, Edouard ;

Ysebaert, Loic ;

Bron, Dominique ;

Soulier, Jean ;

Gaulard, Philippe ;

Houlgatte, Remi ;

Gisselbrecht, Christian ;

Thieblemont, Catherine .

BLOOD, 2012, 119 (20) :4619-4624

← 1 2 3 4 →